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ABSTRACT The World Health Organization estimates that nearly 500 million malaria
tests are performed annually. While microscopy and rapid diagnostic tests (RDTs) are
the main diagnostic approaches, no single method is inexpensive, rapid, and highly
accurate. Two recent studies from our group have demonstrated a prototype com-
puter vision platform that meets those needs. Here we present the results from two
clinical studies on the commercially available version of this technology, the Sight
Diagnostics Parasight platform, which provides malaria diagnosis, species identiﬁca-
tion, and parasite quantiﬁcation. We conducted a multisite trial in Chennai, India
(Apollo Hospital [n  205]), and Nairobi, Kenya (Aga Khan University Hospital [n 
263]), in which we compared the device to microscopy, RDTs, and PCR. For identiﬁ-
cation of malaria, the device performed similarly well in both contexts (sensitivity of
99% and speciﬁcity of 100% at the Indian site and sensitivity of 99.3% and speciﬁc-
ity of 98.9% at the Kenyan site, compared to PCR). For species identiﬁcation, the de-
vice correctly identiﬁed 100% of samples with Plasmodium vivax and 100% of sam-
ples with Plasmodium falciparum in India and 100% of samples with P. vivax and
96.1% of samples with P. falciparum in Kenya, compared to PCR. Lastly, comparisons
of the device parasite counts with those of trained microscopists produced average
Pearson correlation coefﬁcients of 0.84 at the Indian site and 0.85 at the Kenyan site.
KEYWORDS malaria, diagnosis, computer vision, machine learning
Accurate malaria diagnosis prior to treatment is imperative to reduce mortality rates,to prevent antimalarial resistance, and to limit unnecessary side effects from
improperly prescribed drugs (1). As a result, several governmental health organizations
now require malaria testing prior to the use of antimalarials, prompting a projected
increase in demand from 500 million tests in 2012 to 1 billion tests by 2020 (1, 2).
Recent reports show that a large number of malaria carriers maintain low levels of
parasitemia, increasing the need for highly sensitive diagnostic modalities (3, 4).
Microscopy remains the most widely used malaria test worldwide (5, 6). Under con-
trolled laboratory conditions, it is possible to reach a limit of detection of 250 para-
sites/l for thin smears. In most settings, however, microscopy can be very inaccurate,
with typical limits of detection ranging from 300 parasites/l to 1,000 parasites/l, and
requires highly trained staff (7, 8). Several studies have demonstrated poor sensitivity of
microscopy resulting from improperly trained technicians and fatigue due to high test
volumes (9, 10). Recently, rapid diagnostic tests (RDTs) have increased in popularity
since they require minimal training and are considered more consistent than micros-
copy (11). However, RDTs have poor sensitivity at low levels of parasitemia, detect
residual malaria antigens, and are very inconsistent among brands and batches (12, 13).
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The arrival of more sensitive PCR and loop-mediated isothermal ampliﬁcation (LAMP)
assays has shown that many infected individuals are not detected by microscopy and
RDTs. However, these tools are impractical for the vast majority of areas in which
malaria is endemic, due to their high costs and long turnaround times (14, 15).
An automated microscopist could signiﬁcantly improve malaria diagnosis by iden-
tifying live intracellular parasites at low levels of parasitemia with improved speed, cost,
and consistency. Previous attempts at designing an automated microscopist did not
progress past the development stage (16, 17). Recently, our group published two
studies showing that a prototype of such a system could be successful. Srivastava et al.
presented the prototype system (P1), which showed performance results comparable
to those of many marketed RDTs (18). A follow-up article introduced the improved
system (P2), which achieved sensitivity, speciﬁcity, and species identiﬁcation results
comparable to those of expert human microscopists (19).
Here we describe the performance of the commercial Parasight device. We provide
an overview of the technology, as well as the results of clinical studies performed at
Apollo Hospital (Chennai, India) and Aga Khan University Hospital (AKUH) (Nairobi,
Kenya) to evaluate the sensitivity, speciﬁcity, species identiﬁcation, and parasite count
results, compared to standard diagnostic procedures.
RESULTS
Analytical process. The Sight Diagnostics Parasight device is a desktop system for
computerized malaria diagnosis (Fig. 1A). Blood samples are stained and then loaded
into a cartridge that holds ﬁve patient samples (Fig. 1B). After sample loading, a
monolayer forms in the cartridge, with minimal overlap between the blood cells (Fig.
1C). During scanning, the device analyzes stained white blood cells, platelets, red blood
cells (RBCs), and malaria ring-stage parasites, trophozoites, schizonts, and gametocytes
(Fig. 2). In total, the platform records images of 1.5 million red blood cells (0.3 l of
blood). The results are processed by a machine learning algorithm that performs
feature extraction by a computer vision support vector machine (SVM) classiﬁer. The
algorithm examines unique morphological features to reach a ﬁnal diagnosis that
detects, enumerates, and identiﬁes the malaria species (Fig. 3).
Sensitivity and speciﬁcity. At Apollo Hospital and at AKUH, microscopy and PCR
were used as two independent standards for comparison (Tables 1 and 2). At Apollo
Hospital, 205 samples were collected and 5 were discarded due to blood hemolysis; at
AKUH, 263 samples were collected and 6 were discarded due to blood hemolysis. At
FIG 1 Sight Diagnostics malaria platform. (A) Desktop scanning device. (B) Loading cartridge, which holds ﬁve
patient samples. (C) Image of the monolayer at 20, which evenly disperses the blood cells with minimal overlap.
Inset, enlarged image of the monolayer.
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Apollo Hospital, the sensitivity of the RDT was 100% (95% conﬁdence interval [CI], 92.8
to 100%) and the sensitivity of the Parasight system was 99% (95% CI, 94.6 to 99.9%),
in comparison with both microscopy and PCR. The speciﬁcity of the RDT was 97.9%
(95% CI, 92.8 to 99.7%) and the speciﬁcity of the Parasight system was 100% (95% CI,
96.3 to 100%), in comparison with both microscopy and PCR.
At AKUH, the sensitivity of the RDT was 96.8% (95% CI, 92.8 to 98.9%) and the
sensitivity of the Parasight system was 99.3% (95% CI, 97.7 to 100%), in comparison
with microscopy and PCR. The speciﬁcity of the RDT was 94.8% (95% CI, 88.3 to 98.3%)
and the speciﬁcity of the Parasight system was 98.9% (95% CI, 94.4 to 99.7%), in
comparison with microscopy and PCR.
Species identiﬁcation. Species identiﬁcation studies were conducted with samples
provided at Apollo Hospital and AKUH, and the results were compared with PCR
ﬁndings (Table 3). At Apollo Hospital, the RDT showed species identiﬁcation of 98.8%
(95% CI, 93.9 to 99.9%) for Plasmodium vivax and 91.6% (95% CI, 61.5 to 99.7%) for
Plasmodium falciparum, while the Parasight system showed species identiﬁcation of
100% (95% CI, 95.9 to 100%) for P. vivax and 100% (95% CI, 73.5 to 100%) for P.
falciparum. At AKUH, the RDT showed species identiﬁcation of 100% (95% CI, 97.5 to
100%) for P. falciparum and 0% (95% CI, 0 to 26.4%) for P. vivax, while the Parasight
system showed species identiﬁcation of 100% (95% CI, 73.5 to 100%) for P. vivax and
96.1% (95% CI, 91.7 to 98.6%) for P. falciparum.
Parasitemia. At both locations, thin-smear microscopy was performed and para-
sitemia levels were compared to values obtained from the device (Fig. 4A and B). At
Apollo Hospital, the device showed a Pearson correlation coefﬁcient of 0.84, compared
to microscopy (correlation coefﬁcients of 0.98 for P. falciparum and 0.83 for P. vivax); at
AKUH, the device showed a Pearson correlation coefﬁcient of 0.85, compared to
microscopy (correlation coefﬁcients of 0.86 for P. falciparum and 0.55 for P. vivax).
FIG 2 Images of stained blood monolayers. Blood is stained with DNA and RNA dyes and formed into a monolayer. The device
searches for stained white blood cells (A), ring-stage P. falciparum malaria (B), P. vivax gametocytes (C), and P. falciparum gametocytes
(D), as shown by the white arrows.
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DISCUSSION
The increasing demand for highly accurate and rapid malaria testing has created an
unmet need in the malaria diagnostic market. Numerous studies have shown poor
accuracy for both RDTs and microscopists, necessitating the development of new
technologies.
The Parasight platform is a novel malaria test system that is able to provide highly
sensitive malaria evaluations faster than current malaria tests. The system uses a
combination of DNA and RNA ﬂuorescent dyes to stain various blood components. By
using rapidly staining dyes, the device is able to provide rapid diagnoses, as opposed
to antibody-based detection, which requires extensive incubation to detect speciﬁc
antigens. As several cellular entities are stained by the dye combination, the algorithms
use a feature library to distinguish the malaria inside RBCs and to establish the infected
species. The features are based on a database of over 2,500 positive and negative
FIG 3 Algorithm ﬂow diagram. The algorithm begins by identifying candidates, after which it extracts
speciﬁc features and provides a SVM score for each possible parasite. This information is then used to
provide a ﬁnal diagnosis.
TABLE 1 Device sensitivities versus microscopy and PCR
Trial site and method
No. positive/total no. tested (sensitivity [95% CI] [%])
Versus microscopy Versus PCR
Apollo Hospital
RDT 101/101 (100 [92.8–100]) 101/101 (100 [92.8–100])
Microscopy NAa 101/101 (100 [92.8–100])
Parasight 100/101 (99 [94.6–99.9]) 100/101 (99 [94.6–99.9])
AKUH
RDT 155/160 (96.8 [92.8–98.9]) 155/160 (96.8 [92.8–98.9])
Microscopy NA 160/160 (100 [97.7–100])
Parasight 159/160 (99.3 [95.6–99.8]) 159/160 (99.3 [95.6–99.8])
aNA, not applicable.
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patient samples of several different species that were collected from institutions in
Europe, Africa, and India.
Since the publication of the studies by Srivastava et al. and Houri-Yaﬁn et al. (18, 19),
we have signiﬁcantly enlarged the algorithm database of positive and negative sam-
ples, leading to vastly improved performances in all categories. Additionally, we
expanded the features involved in the candidate assessment (as shown in Fig. 3) to
increase the accuracy of the classiﬁer malaria detection and to allow us to lower the
limit of detection to 20 parasites/l. These modiﬁcations have improved the accuracy
of the device from equivalent to a skilled microscopist to equivalent to PCR.
The performance of the device was consistent across different species and use
conditions. Eighty-nine percent of positive samples at Apollo Hospital were P. vivax and
11% were P. falciparum, while 4.3% of positive samples at AKUH were P. vivax and
95.7% were P. falciparum, reﬂecting the different species distributions found in India
and Africa. Additionally, samples from AKUH showed signiﬁcantly higher levels of
parasitemia, with 15% of samples (24/160 samples) having RBC parasite burdens of over
2%, whereas none of the samples from Apollo Hospital had parasitemia over this level.
This discrepancy is likely a function of the higher levels of parasitemia found intrinsi-
cally in P. falciparum infections, compared with other varieties of malaria.
While the device performed very accurately, there were several notable cases of
discrepancies for which we found explanations. One patient sample at Apollo Hospital
and one at AKUH were incorrectly diagnosed as negative by the Parasight system, due
to levels of parasitemia below 20 parasites/l. At AKUH, several P. falciparum cases were
erroneously identiﬁed as P. vivax both by the local microscopists and by the device.
Careful review of those samples found that the errors were caused by large trophozo-
ites that resembled P. vivax instead of P. falciparum. One sample at AKUH was assessed
as a false-positive sample when the Parasight system result was compared to the PCR
result, due to an extremely high level of Howell-Jolly bodies. Finally, while most of the
correlation coefﬁcients for the parasitemia levels were high (0.8), the correlation
coefﬁcient for P. vivax in the AKUH experiment was only 0.55; this stemmed from the
very small number of P. vivax samples included in the study (8) and the lack of
TABLE 2 Device speciﬁcities versus microscopy and PCR
Trial site and method
No. positive/total no. tested (speciﬁcity [95% CI] [%])
Versus microscopy Versus PCR
Apollo Hospital
RDT 97/99 (97.9 [92.8–99.7]) 97/99 (97.9 [92.8–99.7])
Microscopy NAa 99/99 (100 [96.3–100])
Parasight 99/99 (100 [96.3–100]) 99/99 (100 [96.3–100])
AKUH
RDT 92/97 (94.8 [88.3–98.3]) 92/97 (94.8 [88.3–98.3])
Microscopy NA 97/97 (100 [96.1–100])
Parasight 96/97 (98.9 [94.4–99.7]) 96/97 (98.9 [94.3–99.9])
aNA, not applicable.
TABLE 3 Species identiﬁcation accuracy
Trial site and method
No. identiﬁed/total no. tested (identiﬁcation [95% CI] [%])
P. falciparum P. vivax
Apollo
RDT 11/12 (91.6 [61.52–99.7]) 88/89 (98.8 [93.9–99.9])
Microscopy 12/12 (100 [73.5–100]) 89/89 (100 [95.9–100])
Parasight 12/12 (100 [73.5–100]) 89/89 (100 [95.9–100])
AKUH
RDT 148/148 (100 [97.5–100]) 0/7 (0 [0–26.4])
Microscopy 147/153 (96.1 [91.7–98.6]) 7/7 (100 [73.5–100])
Parasight 147/153 (96.1 [91.7–98.6]) 7/7 (100 [73.5–100])
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familiarity of the microscopists with this strain, due to its rarity in the region. It is
important to note also that these discrepancies might have emerged due to changes
in cell morphology that occurred in 24-h-old samples. Additionally, future adaptions
will be made in the algorithm to ﬂag samples with high Howell-Jolly body levels for
additional testing.
It is important to note that the high sensitivity and speciﬁcity values for microscopy
at these sites do not reﬂect standard practices and results. Three expert microscopists
reviewed all slides, with a minimum of 10 views per slide, while at most locations a
single technician brieﬂy reviews each slide. Therefore, the true sensitivity of microscopy
in normal laboratory settings is closer to 500 parasites/l, as cited elsewhere in the
literature (20). The performance of the RDT at AKUH was in line with previously
reported ﬁndings, while the RDT at Apollo Hospital showed superior accuracy, com-
pared to prior results; this was also likely due to the highly controlled environment in
which the test was performed, which is not reﬂective of standard ﬁeld results. The RDT
species identiﬁcation at AKUH was very poor for P. vivax, but the RDT at Apollo Hospital
performed well in species identiﬁcation of both P. vivax and P. falciparum. This again
shows great interbrand and interspecies variability among RDTs, which makes them
difﬁcult for clinicians to interpret.
FIG 4 Microscopy results versus device results. (A) At AKUH, microscopy parasitemia levels correlated
with Sight Diagnostics (SightDx) parasitemia levels with a Pearson correlation coefﬁcient of 0.85. (B) At
Apollo Hospital, microscopy parasitemia levels correlated with Sight Diagnostics parasitemia levels with
a Pearson correlation coefﬁcient of 0.84.
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Several updates are currently under development to improve the diagnostic per-
formance of the Parasight system, due to the limitations of the current study. The
current device has a limit of detection of 20 parasites/l. Future versions of the
algorithm will provide detection capabilities that could be as low as 5 parasites/l, by
better differentiating between malaria parasites and objects with similar morphological
features (such as Howell-Jolly bodies). Additionally, the device is currently unable to
distinguish between P. vivax and Plasmodium ovale, as few P. ovale samples have been
collected to train the algorithm. While this is less problematic clinically, as the two
forms of malaria infections require the same medication regimens, distinguishing
between the two is important for epidemiological considerations. With a signiﬁcant
number of operational devices, we will be able to build a large enough library of P.
ovale samples to enable the classiﬁer to distinguish the species.
Taken together, these ﬁndings indicate that the Parasight platform demonstrates
improved accuracy, compared with our previous prototype devices, and provides
signiﬁcant value for the malaria diagnostic community. The distribution of the device
at strategic locations will lead to improved disease treatment and screening, ultimately
resulting in an expedited roadmap to eradication.
MATERIALS AND METHODS
Study design. The study was a two-center, prospective, blinded trial conducted with blood samples
from patients with clinically suspected malaria, at Apollo Hospital (Chennai, India) (n  205) and at Aga
Khan University Hospital (Nairobi, Kenya) (n  263). Ethics committee approval was obtained for the use
of all samples.
Sample collection. Determination of eligibility for malaria treatment was based solely on the
standard diagnostic protocols of the clinics and the patient treatment courses and was not altered due
to the study or results from the Sight Diagnostics diagnostic device. At all locations, venous blood
samples were collected in EDTA-containing Vacutainer tubes and were analyzed by RDTs, microscopy,
and the Parasight device within 48 h after collection.
RDTs. For the purpose of comparison, RDTs were performed with all samples. At Apollo Hospital, the
Alere Trueline test was used for RDT analysis, according to the manufacturer’s directions. At AKUH, the
SD Bioline test was used for RDT analysis, according to the manufacturer’s directions.
Microscopy. At both locations, thin-smear microscopy was performed independently by three expert
microscopists, who agreed upon a ﬁnal diagnosis. Parasite counts were performed via light microscopy
for all samples in a standardized manner, representing ideal (rather than typical) conditions. The
microscopists analyzed at least 10 ﬁelds at 100 magniﬁcation, with approximately 100 RBCs being
counted per ﬁeld. Parasitemia levels were calculated as the ratio of infected RBCs to total RBCs.
Gametocytes were not included in the ﬁnal parasite counts.
PCR. At Apollo Hospital and at AKUH, all samples were reviewed by real-time PCR according to a
previously described protocol (19). Brieﬂy, real-time PCR was performed with Fast Sybr Green master mix
in a volume of 10 l (Applied Biosystems), to identify P. falciparum, P. vivax, and Plasmodium in general.
All reactions were performed in 384-well quantitative PCR plates (Bio-Rad) in a CFX384 real-time PCR
system (Bio-Rad).
Sight Diagnostics device analysis. At both locations, digital imaging was carried out onsite with the
commercially available Parasight platform. Five microliters of each blood sample was mixed with 500 l
of a ﬂuorescent dye solution, and the sample was loaded into a plastic cartridge. The cartridge was then
incubated at room temperature for 10 min, during which time the cells formed a monolayer. The
cartridge was inserted into the device and scanned with three different light-emitting diode (LED) light
sources (370 nm, 475 nm, and 530 nm). The total scan time per sample was 4 min and the device held
up to 30 samples, which could be loaded in a batch or individually. Approximately 800 images were
scanned per sample, and the algorithm processed individual images in real time. If a sample was
incorrectly prepared, an error resulted and the process was repeated. Errors could result from too little
or too much blood used in sample preparation, dirt on the cartridge, or improper preparation of the
working stain solution. Computer vision and statistical models were used to determine infection status,
parasitemia levels, and species.
Analysis. Both microscopy and PCR were used as a basis for comparison for the results. In many
settings, microscopy is considered more accurate than PCR, as it identiﬁes live intracellular parasites and
is not subject to errors caused by circulating DNA from ablated parasites. Therefore, sensitivity and
speciﬁcity were calculated in comparison with microscopy and PCR independently. In all calculations for
which the comparison standard is not noted, PCR is used as the standard for comparison.
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